source
- Lilly's retatrutide outperforms Ozempic in phase 3 trial, cutting blood sugar and weight moreEli Lilly tested its triple-G candidate retatrutide against Novo Nordisk's Ozempic (semaglutide) in an open-label phase 3 study involving about 1,300 adults with type 2 diabetes whose glucose was n…
- Big pharma holds $188 bn for M&A, J&J seen as most likely buyer, analysis showsThe latest Leerink Partners analysis finds that the largest pharmaceutical companies collectively have about $188 billion in cash available for mergers and acquisitions. All but one of the firms su…